Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study

Author： Chen Kai   Chen Wan   Chen Xia   Jia Yi   Peng Gui   Chen Li  

Publisher： Springer Publishing Company

ISSN： 0378-7966

Source： European Journal of Drug Metabolism and Pharmacokinetics, Vol.39, Iss.1, 2014-03, pp. : 25-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Paclitaxel plus cisplatin and lonidamine showed `good activity' in advanced ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1285, 2001-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Paclitaxel plus cisplatin increases survival, costs in ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1345, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Paclitaxel plus cisplatin increases survival, costs in ovarian cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 370, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Paclitaxel vs cyclophosphamide, + cisplatin, for ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Cisplatin plus paclitaxel superior in cervical cancer?

By  

Inpharma, Vol. 1, Iss. 1284, 2001-01 ,pp. : 14-15

Adis International

Access to resources Recommend Favorite